Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC
Frisoni, G. B.; Scheltens, P. H.; Galluzzi, S.et al.
2003 • In Journal of Neurology, Neurosurgery and Psychiatry, 74 (10), p. 1371-1381
[en] Neuroimaging is a mainstay in the differential diagnosis of patients with cognitive impairment. The often equivocal clinical pictures, the prognostic uncertainty of the earliest stages of mild cognitive impairment, and the subtle brain changes mean that neuroimaging techniques are of potentially great incremental diagnostic value. A number of methods, ranging from very simple subjective visual ratings to highly sophisticated computerised tools, have been developed, which allow rating of structural and functional brain changes. The choice of the method is not obvious, and current guidelines provide no indications on which tools should be preferred. In this paper, we give indications for tools with demonstrated accuracy for detecting regional atrophy, cerebrovascular disease, and regional brain function, and discuss these according to increasing technological complexity, ranging from those with high feasibility that can be used at the patient's bedside to highly technological ones that require trained personnel and specific hardware and software.
Disciplines :
Neurology
Author, co-author :
Frisoni, G. B.
Scheltens, P. H.
Galluzzi, S.
Nobili, F. M.
Fox, N. C.
Robert, P. H.
Soininen, H.
Wahlund, L. O.
Waldemar, G.
Salmon, Eric ; Université de Liège - ULiège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Language :
English
Title :
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC
Practice parameter for diagnosis and evaluation of dementia. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994;44:2203-6.
Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13-21.
Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology 2000;55:1854-62.
Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology 2000;55:1863-9.
Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403.
Johnson KA, Jones K, Holman BL, et al. Precli imaging, cognitive impairment, Alzheimer, atrophy, cerebrovascular disease, rating scales. Nical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-71.
Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [(123)I]iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's Disease. Am J Psychiatry 2002;159:474-6.
Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-7.
Fox NC, Cousens S, Scahill R, et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339-44.
Peripheral and Central Nervous System Drugs Advisory Committee. Joint Meeting with Medical Imaging Drugs Advisory Committee; November 18-19, 2002. http://www.fda.gov/ohrms/dockets/ac/cder02.htm# Peripheraland Central Nervous System Drugs. Accessed May 23, 2003.
Roman G-C, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neurol Transm Suppl 2000;59:23-30.
Waldemar G, Dubois B, Emre M, et al. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol 2000;7:133-44.
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
Bosscher L, Scheltens P. MRI of the medial temporal lobe for the diagnosis of Alzheimer's disease. In: Qizilbash N, ed. Evidence-based dementia practice. Oxford: Blackwell Science, 2002:154-62.
Goethals I, Van De Wiele C, Slosman D, et al. Brain SPET perfusion in early Alzheimer's disease: where to look? Eur J Nucl Med Mol Imaging 2002;29:975-8.
Holloway F. Outcome measurement in mental health-welcome to the revolution. Br J Psychiatry 2002;181:1-2.
Scheltens P, Erkinjunti T, Leys D, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur J Neurol 1998;39:80-9.
Ashburner J, Csernansky JG, Davatzikos C, et al. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol - 2003;2:79-88.
Salmon E. Functional brain imaging applications to differential diagnosis in the dementias. Curr Opin Neurol 2002;15:439-44.
Wahlund LO, Barkhof F, Fazekas F, et al. European Task Force on Age-Related White Matter Changes: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-22.
Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomograpny. Lancet 1992;340:1179-83.
Gao FQ, Black SE, Leibovitch FS, et al. A reliable MR measurement of medial temporal lobe width from the Sunnybrook Dementia Study. Neurobiol Aging 2003;24:49-56.
Frisoni GB, Beltramello A, Weiss C, et al. Linear measures of atrophy in mild Alzheimer disease. Am J Neuroradiol 1996;17:913-23.
Denihan A, Wilson G, Cunningham C, et al. CT measurement of medial temporal lobe atrophy in Alzheimer's disease, vascular dementia, depression and paraphrenia. Int J Geriatr Psychiatry 2000;15:306-12.
Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994;343:829-30.
Frisoni GB, Geroldi C, Beltramello A, et al. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. Am J Neuroradiol 2002;23:35-47.
Laakso MP, Frisoni GB, Kononen M, et al. Hippocampus and entorhinal cortex in frontotemporal dementia. A qualitative MRI study. Biol Psychiatry 2000;47:1056-63.
Frisoni GB, Rossi R, Beltramello A. The radial width of the temporal horn in mild cognitive impairment. J Neuroimaging 2002;12:351-4.
Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72.
Wahlund LO, Julin P, Johansson SE, et al. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry 2000;69:630-5.
Visser PJ, Verhey FR, Hofman PA, et al. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002;72:491-7.
Rockwood K, Parhad I, Hachinski V, et al. Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research concensus statement. Can J Neurol Sci 1994;21:358-64.
Lopez OL, Becker JT, Jungreis CA, et al. Computed tomography - but not magnetic resonance imaging-identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol 1995;52:659-64.
Pantoni L, Leys D, Fazekas F, et al. Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 1999;13(Suppl 3):S49-54.
Frisoni GB, Padovani A, Wahlund LO. The diagnosis of Alzheimer's disease before it is Alzheimer's dementia. Arch Neurol 2003, in press.
Du AT, Schuff N, Amend D, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:441-7.
Jack CR Jr, Bentley MD, Twomey CK, et al. MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology 1990;176:205-9.
Laakso MP Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology 1996;46:678-81.
Laakso MP, Soininen H, Partanen K, et al. MRI of the hippocampus in Alzheimer's disease: sensitivity specificity and analysis of the incorrectly classified subjects. Neurobiol Aging 1998;19:23-31.
DeCarli C, Maisog J, Murphy DG, et al. Method for quantification of brain ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 1992;16:274-84.
Ge Y, Grossman RI, Babb JS, et al. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis, AJNR Am J Neuroradiol 2002;23:1327-33.
Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-89.
DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001;58:643-7.
Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy n Alzheimer's disease. Lancet 1996;348:94-7.
Chan D, Fox NC, Jenkins R, et al. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001;57:1756-63.
Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997;7:1069-75.
Fox NC, Scahill RI, Crum WR, et al. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999;52:1687-9.
Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996;119:2001-7.
Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001;358:201-5.
Perani D. The role of emission tomography in dementia. Ital J Neurol Sci 1999;20(Suppl 5):S254-7.
Messa C, Perani D, Lucignani G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. J Nucl Med 1994;35:210-16.
Waldemar G, Bruhn P, Kristensen M, et al. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study. J Neurol Neurosurg Psychiatry 1994;57:285-95.
Jagust W, Thisted R, Devous MD Sr, et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001;56:950-6.
Pearlson GD, Harris GJ, Powers RE, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry 1992;49:402-8.
Jobst KA, Smith AD, Barker CS, et al. Assaciation of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992;55:190-4.
Scheltens P, Launer LJ, Barkhof F, et al. The diagnostic value of magnetic resonance imaging and technetium 99 m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Alzheimer Dis Assoc Disord 1997;11:63-70.
Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7.
O'Brien JT, Ames D, Desmond P, et al. Combined magnetic resonance imaging and single-photon emission tomography scanning in the discrimination of Alzheimer's disease from age-matched controls. Int Psychogeriatr 2001;13:149-61.
Signorini M, Paulesu E, Friston K, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage 1999;9:63-80.
Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001;15:85-92.
De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39.
de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71.
Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-9.
Van Laere KJ, Warwick J, Versijpt J, et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med 2002;43:458-69.
Nobili F, Koulibaly M, Vitali P, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002;43:983-90.
Frisoni GB. Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. J Neurol Neurosurg Psychiatry 2001;70:711-18.
Fontaine S, Bourgouin P. Structural brain imaging in Alzheimer's disease. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1999:107-16.
Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643-9.
Middelkoop HA, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001;57:2117-20.
Thompson PM, Mega MS, Toga AW. Disease-specific brain atlases. In: Toga AW, Mazziotta JC, eds. Brain mapping: the disorders. Academic Press, 2000:131-77.
Woermann FG, Free SL, Koepp MJ, Ashburner J, et al. Voxel-by-voxel comparison of automatically segmented cerebral gray matter - a rater-independent comparison of structural MRI in patients with epilepsy. NeuroImage 1999;10:373-84.
Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169-75.
Snowdon DA, Greiner LH, Mortimer JA, et al. Brain inforction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-7.
Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-9.
DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-84.
Zijlmans JC, Thijssen HO, Vogels OJ, et al. MRI in patients with suspected vascular parkinsonism. Neurology 1995;45:2183-8.
O'Brien J, Ames D, Chiu E, et al. Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ 1998;317:982-4.
Tonkonogy JM, Geller JL. Late-onset paranoid psychosis as a distinct clinicopathologic entity: magnetic resonance imaging data in elderly patients with paranoid psychosis of late onset and schizophrenia of early onset. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:230-5.
Benson RR, Guttmann CR, Wei X, et al. Older people with impaired mobility have specific loci of periventricular abnormality on MRI. Neurology 2002;58:48-55.
Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12:851-5.
Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-34.
Chetelat G, Baron J-C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. NeuroImage 2003;18:525-41.
Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′ -methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-92.
Skovronsky DM, Zhang B, Kung MP, et al. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:7609-14.
Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226:315-36.
Small GW, Agdeppa ED, Kepe V, et al. In vivo brain imaging of tangle burden in humans. J Mol Neurosci 2002;19:323-7.
Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ 2002;324:539-41.
Hillman BJ. Medical imaging in the 21st century. Lancet 1997;350:731-3.
